Recce Ltd has released a press release.
Recce Receives AUD $11.17m R&D Advance
Filed with ASX ·
6ix hasn’t read this filing yet.
Recce Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Recce Pharmaceuticals
- Safety Committee Approves Expansion of Ph I/II DFI Trial
- RCE Establishes Strategic Partnership in South-East Asia
- Positive Ph I/II DFI Efficacy Data to Support Site Expansion
- Murdoch Children's R327 Efficacy UTI in-vivo
- RCE Awarded Further $11.17m Advanced Overseas Finding
Later from Recce Pharmaceuticals
- Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
- Patent Granted in Israel for RECCE Anti-Infectives
- Recce Pharmaceuticals - Business Update
- Recce Completes 5,000 R327 Doses Per Week under GMP
- Safety Committee Approves High Dose of 4,000mg
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals